Experimental and theoretical spectroscopic studies on selected igepals

Several nonionic igepals characterized by the formula (CmH2m+1 )-C6H4-(OCH2CH2 ) n OH were investigated by high resolution NMR and IR spectroscopy. Gauge invariant atomic orbital density functional theory NMR calculations on model molecules in the gas phase additionally supported the assignment of experimental carbon signals. Different orientations of individual sub-units of an aliphatic chain relative to external magnetic field and trans-gαuche transitions were assumed to explain complex patterns of carbon spectra in the aliphatic region of igepals with linear alkyl chain

Violation of Boltzmann Equipartition Theorem in Angular Phonon Phase Space Slows down Nanoscale Heat Transfer in Ultrathin Heterofilms

Heat transfer through heterointerfaces is intrinsically hampered by a thermal boundary resistance originating from the discontinuity of the elastic properties. Here, we show that with shrinking dimensions the heat flow from an ultrathin epitaxial film through atomically flat interfaces into a single crystalline substrate is significantly reduced due to violation of Boltzmann equipartition theorem in the angular phonon phase space. For films thinner than the phonons mean free path, we find phonons trapped in the film by total internal reflection, thus suppressing heat transfer. Repopulation of those phonon states, which can escape the film through the interface by transmission and refraction, becomes the bottleneck for cooling. The resulting nonequipartition in the angular phonon phase space slows down the cooling by more than a factor of 2 compared to films governed by phonons diffuse scattering. These allow tailoring of the thermal interface conductance via manipulation of the interface

Evolution of Microstructure and Texture during Warm Rolling Of a Duplex Steel

The effect of warm rolling on the evolution of microstructure and texture in a duplex stainless steel (DSS) was investigated. For this purpose, a DSS steel was warm rolled up to 90 pct reduction in thickness at 498 K, 698 K, and 898 K (225 °C, 425 °C, and 625 °C). The microstructure with an alternate arrangement of deformed ferrite and austenite bands was observed after warm rolling; however, the microstructure after 90 pct warm rolling at 498 K and 898 K (225 °C and 625 °C) was more lamellar and uniform as compared to the rather fragmented and inhomogeneous structure observed after 90 pct warm rolling at 698 K (425 °C). The texture of ferrite in warm-rolled DSS was characterized by the presence of the RD (〈011〉//RD) and ND (〈111〉//ND) fibers. However, the texture of ferrite in DSS warm rolled at 698 K (425 °C) was distinctly different having much higher fraction of the RD-fiber components than that of the ND-fiber components. The texture and microstructural differences in ferrite in DSS warm rolled at different temperatures could be explained by the interaction of carbon atoms with dislocations. In contrast, the austenite in DSS warm rolled at different temperatures consistently showed pure metal- or copper-type deformation texture which was attributed to the increase in stacking fault energy at the warm-rolling temperatures. It was concluded that the evolution of microstructure and texture of the two constituent phases in DSS was greatly affected by the temperature of warm rolling, but not significantly by the presence of the other phas

Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. RESULTS: During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, -0.29 percentage points; 95% confidence interval [CI], -0.32 to -0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P = 0.98). There were no significant between-group differences in rates of acute pancreatitis (P = 0.07) or pancreatic cancer (P = 0.32). CONCLUSIONS: Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Nuclear Spin Relaxation in Periodically Perturbed Systems

The effective relaxation time T$\text{}_{2e}$ is calculated in the weak collision case for a system of identical nuclear spins perturbed by periodic sequences of r.f. pulses and dipole-dipole and quadrupole interactions

Nuclear Spin Relaxation in Periodically Perturbed Systems. II. Like and Unlike Spins

The effective relaxation time T$\text{}_{2e}$ is calculated in the weak collision case for a system consisting of resonant nuclear spins I and nonresonant spins S, perturbed by periodic sequences of r.f. pulses and dipole-dipole interactions

Analysis of selected problems encountered while testing natural gas-condensate fields in the Western Carpathians

The potential change of natural gas composition in the near-wel lbore zone creates a big problem with the selection of appropriate initial value of counterpressure exerted by the displacement fluid on reservoir during the test, and also with the interpretation of the reservoir and production tests results. The analysis of the industrial data reveals that the effect of condensate production in the near-wellbore zone could take place while using too high counterpres-sure during DST tests, as a consequence of using a relatively high column of water displacement fluid in the DST column, i.e. about 2500 m. This thesis can be confirmed after further detailed theoretical analysis of the occurring thermodynamic conditions. The paper addresses technological and interpretation problems encountered during drill stem tests (DST) of gas-bearing Devonian strata, on the example of the Stryszawa field in the Western Carpathians. Special attention was paid to the possible changes of gas compo sition during flow tests and the cases of gas condensation of heavier fractions during build-up tests. Attempts were made at explaining sudden drops of pressure at the build-up stage along with the thermodynamic conditions responsible for this effect. The authors explained the necessity of using an appropriate Ful-Flo sampler in the DST set for collecting gas samples at any time of the test, and devices for continuous measurement of temperature. The use of new types of drill stem testers and appropriate interpretation methods, which would account for a detailed analysis of technological and reservoir conditions allows for more efficient oil prospecting and deciding about enhancement methods in hydrocarbon production. The analysis of thermodynamic conditions on the bottom of the wellbore allow s for selecting proper counterpressure values in view of the condensation of heavier gas fractions in the near wellbore rocks. The analysis of conditions in which heavier gas fractions undergo condensation is approximate and general because the gas samples were collected at the outlet of the DST string (in surface conditions), without a Ful-Flo sampler and without temperature measurements